| 颜红芳,周吕蒙,梁华,等.血清三叶因子 3、胃泌素 17、膜联蛋白 A7联合检测对胃癌及癌前病变的临床诊断价值[J].安徽医药,2021,25(10):2057-2060. |
| 血清三叶因子 3、胃泌素 17、膜联蛋白 A7联合检测对胃癌及癌前病变的临床诊断价值 |
| Clinical diagnostic value of combined detection of serum trefoil factor 3, gastrin 17 and annexin A7 in gastric cancer and precancerous lesions |
| |
| DOI：10.3969/j.issn.1009-6469.2021.10.034 |
| 中文关键词: 胃肿瘤 癌症早期检测 三叶因子 3 胃泌素 -17 膜联蛋白 A7 癌前状态 |
| 英文关键词: Stomach neoplasms Early detection of cancer Trefoil factor 3 Gastrin-17 Annexin A7 Precancerous conditions |
| 基金项目: |
|
| 摘要点击次数: 1656 |
| 全文下载次数: 623 |
| 中文摘要: |
| 目的探讨血清三叶因子 3(TFF3)、胃泌素 -17(G-17)联合膜联蛋白 A7(ANXA7)对胃癌及癌前病变的临床诊断价值。方法 2018年 1月至 2019年 12月选取攀枝花市攀钢集团总医院收治的经病理组织学确诊为胃部病变病人 168例，另选取 60例健康体检者为对照组，采用酶联免疫吸附测定法( ELISA)测定各组血清 TFF3、G-17、ANXA7水平，并应用受试者特异性曲线(ROC)分析血清 TFF3、G-17、ANXA7在胃癌及癌前病变临床诊断中的应用价值。结果低级别上皮内瘤变( LGIN)组、高级别上皮内瘤变( HGIN)组及胃癌组血清 TFF3、G-17、ANXA7水平［TFF3(38.25±4.10)μg/L比( 52.92±5.26)比( 78.36±6.89)； G-17(14.85±3.26)mmol/L比( 23.69±4.58)mmol/L比( 35.96±5.85)mmol/L；ANXA7(22.36±3.96)μg/L比( 38.96±4.89)μg/L比( 52.36±6.25)μg/L］明显高于萎缩性胃炎、浅表胃炎组及对照组［TFF3:(14.58±3.22)μg/L比( 14.85±2.73)比( 14.15±2.10)； G-17(8.69±1.36)mmol/L比( 8.16±1.18)mmol/L比( 8.12±1.02)mmol/L；ANXA7(10.78±1.78)μg/L比( 10.26±1.26)μg/L比( 10.12±1.26)μg/L］(P<0.05)。不同 TNM分期、分化程度及淋巴结转移胃癌组病人血清 TFF3、G-17、ANXA7水平差异有统计学意义( P<0.05)。经 ROC曲线分析可知，血清 TFF3、G-17、ANXA7诊断胃癌及癌前病变的 AUC(95%CI)分别为 0.844(0.731～0.974)、0.717(0.558～0.921)、0.748(0.578～0.968)。联合应用的诊断价值更高， AUC(95%CI)为 0.880(0.823～0.941)，灵敏度和特异度分别为 0.903、0.872。结论血清 TFF3、G17、ANXA7水平与胃组织癌前期病变，胃癌分期、分化程度以及淋巴结转移密切相关，可作为胃癌病人预后的评价指标，联合应用可提高其诊断效能。 |
| 英文摘要: |
| Objective To explore the clinical diagnostic value of combined detection of serum trefoil factor 3 (TFF3), gastrin 17 (G17) and annexin A7 (ANXA7) in gastric cancer and precancerous lesions.Methods A hundred and sixty-eight cases of patients withgastric lesions diagnosed by gastroscopy in General Hospital of Panzhihua Iron & Steel Group from January 2018 to December 2019were enrolled in the study. Another 60 healthy subjects were selected as the control group. The expression levels of serum TFF3, G-17, and ANXA7 of each group were determined by the enzyme-linked immunosorbent assay (ELISA).The value of serum TFF3,G-17, ANXA7 in the clinical diagnosis of gastric cancer was analyzed by receiver operating characteristic curve (ROC).Results The levels of TFF3, G-17 and ANXA7 in low-grade intraepithelial neoplasia (LGIN) group, high-grade intraepithelial neoplasia (HGIN) group and gastric cancer group [TFF3: (38.25±4.10) , (52.92±5.26) and (78.36±6.89) ; G-17: (14.85±3.26) mmol/L, (23.69±4.58) mmol/L and(35.96±5.85) mmol/L; ANXA7:(22.36±3.96) μg/L, (38.96±4.89) μg/L and (52.36±6.25) μg/L] were significantly higher than gastritisgroup, superficial gastritis and the control group [TFF3:(14.58±3.22) ,(14.85±2.73) and (14.15±2.10) ; G-17:(8.69±1.36) mmol/L,(8.16±1.18) mmol/L and (8.12±1.02) mmol/L; ANXA7:(10.78±1.78) μg/L, (10.26±1.26) μg/L and (10.12±1.26) μg/L] (P<0.05).There were significant differences in serum TFF3, G-17 and ANXA7 levels among patients with different TNM stage, degree of differentiation and lymph node metastasis (P<0.05). ROC curve analysis results showed that the AUC (95%CI) of serum TFF3, G-17 and ANXA7 in the diagnosis of gastric cancer and precancerous lesions were 0.844 (0.731-0.974), 0.717 (0.558-0.921) and 0.748 (0.578-0.968), respectively. Combined application was of higher diagnostic value, with an AUC (95%CI) of 0.880 (0.823-0.941), sensitivity and specificity of |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
